EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Benzimidazole–Triazole Hybrids for Single- and Multi-Target Protein Kinase Inhibition

Hamzeh M Abu Al Rub, Ahmed G Eissa iD

Pharmaceuticals · 15.04.2026 · 19 (4) · 623

DOI: 10.3390/ph19040623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 15.04.2026. Verfasst von Hamzeh M Abu Al Rub und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Al Ain University, Abu Dhabi 64141, United Arab Emirates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al Ain University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Protein kinases play a crucial role in cancer initiation, progression, and therapeutic resistance by regulating signalling pathways involved in tumour growth and survival. Consequently, they represent major targets in anticancer drug discovery. Among heterocyclic scaffolds explored in kinase inhibitor design, benzimidazole has emerged as a privileged structure due to its strong hydrogen-bonding capability and structural resemblance to purine moieties. Triazole motifs are also widely incorporated into bioactive molecules because of their metabolic stability, favourable electronic properties, and ability to establish key interactions within kinase active sites. This review aims to summarise and critically discuss benzimidazole- and triazole-based kinase inhibitors, both as individual scaffolds and as hybrid systems, with emphasis on their kinase targets and multitarget potential.

Methods

The relevant literature was surveyed from major scientific databases focusing on studies describing the synthesis, biological evaluation, and molecular modelling of benzimidazole- and triazole-containing kinase inhibitors.

Results

Numerous studies demonstrate that both benzimidazole and triazole scaffolds exhibit significant kinase inhibitory activity against oncogenic targets, including EGFR, cyclin-dependent kinases (CDKs), and components of the PI3K/Akt/mTOR signalling pathway. Hybrid molecules combining these pharmacophores frequently enhance binding interactions and facilitate the development of multitarget kinase inhibitors. Structure–activity relationship trends indicate that pharmacophore accessibility, substitution patterns, and linker architecture influence inhibitory potency and selectivity.

Conclusions

Overall, benzimidazole- and triazole-based scaffolds represent promising platforms for developing next-generation multitarget anticancer agents and provide valuable insights for the rational design of improved kinase inhibitors.

Schlagwörter

Stichwörter der Autor:innen

Benzimidazoleanticancerheterocyclic scaffoldskinase inhibitorsmultitargettriazole

Autor:innen und Institutionen

  • College of Pharmacy, Al Ain University, Abu Dhabi 64141, United Arab Emirates.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.

ORCID-Profile: Ahmed G Eissa

Förderung

  • Al Ain University

Zitieren

APA

Abu Al Rub, H. M., & Eissa, A. G. (2026). Recent Advances in Benzimidazole–Triazole Hybrids for Single- and Multi-Target Protein Kinase Inhibition. Pharmaceuticals, 19(4), 623. https://doi.org/10.3390/ph19040623

Vancouver

Abu Al Rub HM, Eissa AG. Recent Advances in Benzimidazole–Triazole Hybrids for Single- and Multi-Target Protein Kinase Inhibition. Pharmaceuticals. 2026;19(4):623. doi:10.3390/ph19040623

BibTeX
@article{AbuAlRub2026,
  author = {Abu Al Rub, Hamzeh M and Eissa, Ahmed G},
  title = {Recent Advances in Benzimidazole–Triazole Hybrids for Single- and Multi-Target Protein Kinase Inhibition},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {623},
  doi = {10.3390/ph19040623}
}
Kostenlos starten →